Skip to main content

Table 6 Quality of life score according to the Time after completion of treatment (months) and cervical cancer stage (FIGO) of the CC patients

From: Quality of life among cervical cancer patients following completion of chemoradiotherapy at Ocean Road Cancer Institute (ORCI) in Tanzania

QLQ Items

Time after treatment completion (months)

P*

Figo Stage

P#

3–12

 > 13

I

II

III

IV

n = 237

n = 86

n = 33

n = 195

n = 47

n = 10

QLQ-C30 Functional scales

Global Health Status/QOL

63 ± 16.8

68.2 ± 19.4

0.021

64.6 ± 17.7

62.9 ± 17.8

68.3 ± 18.0

61.7 ± 13.5

0.238

Physical Functioning

85 ± 14.1

87.8 ± 15.8

0.016

86.7 ± 14.2

85.1 ± 14.3

84.1 ± 15.0

79.3 ± 11.6

0.393

Role Functioning

88.9 ± 19.1

93.6 ± 16.0

0.007

90.4 ± 15.6

90.6 ± 19.0

83.0 ± 19.9

90.0 ± 11.8

0.054

Emotional Functioning

81.2 ± 22.3

77.8 ± 23.8

0.289

86.4 ± 23.7

80.7 ± 23.0

75.0 ± 23.2

82.5 ± 21.8

0.035

Cognitive Functioning

79.0 ± 25

88.2 ± 19.3

0.003

82.8 ± 22.2

80.9 ± 23.7

78.7 ± 24.8

88.3 ± 28.6

0.582

Social Functioning

71.7 ± 31.1

85.3 ± 25.9

0.000

73.2 ± 27.6

73.1 ± 32.0

78.4 ± 31.5

81.7 ± 28.2

0.749

QLQ-C30 Symptom scales

Fatigue

17.3 ± 18.6

13 ± 19.2

0.010

14.8 ± 16.8

16.3 ± 19.3

21.3 ± 19.6

31.1 ± 18.4

0.025

Nausea & Vomiting

4.9 ± 14.2

5.8 ± 17.7

0.865

2.0 ± 6.9

5.0 ± 15.9

8.2 ± 16.5

6.7 ± 12.1

0.319

Pain

20.1 ± 22.1

19 ± 25.1

0.248

17.7 ± 19.1

20 ± 23.2

25.9 ± 23.6

26.7 ± 24.7

0.354

Dyspnea

3.4 ± 14

5.8 ± 14.6

0.024

3.0 ± 12.8

3.2 ± 12.9

6.4 ± 14.5

16.7 ± 29.4

0.034

Insomnia

12.7 ± 23.8

13.6 ± 29.1

0.577

9.1 ± 20.9

13 ± 25.1

20.6 ± 26.3

0

0.038

Appetite Loss

8.8 ± 20.9

9.3 ± 23.8

0.712

7.1 ± 16.2

7.9 ± 21.4

13.5 ± 21.7

10.0 ± 16.7

0.128

Constipation

21.7 ± 28.1

11.6 ± 24.4

0.001

13.1 ± 24.9

20.2 ± 27.6

24.1 ± 28.7

6.7 ± 22.2

0.114

Diarrhea

2.5 ± 12.4

7.4 ± 22.5

0.034

3 ± 17.4

3.9 ± 15.6

2.1 ± 15.6

10.0 ± 33.3

0.807

Financial difficulties

63.2 ± 35.4

65.1 ± 39.9

0.661

55.6 ± 37

64.6 ± 37.2

63.8 ± 36.7

56.7 ± 44.4

0.600

QLQ-CX24 Symptom scales

Symptom Experience

13.8 ± 10.9

15.1 ± 12.9

0.533

13.8 ± 11.3

14.2 ± 11.9

14.9 ± 11.7

13.5 ± 11.7

0.906

Body Image

21.1 ± 27.3

15.8 ± 23.6

0.212

19.2 ± 24.1

22.3 ± 27.0

16.8 ± 27.1

10.0 ± 29.4

0.078

Sexual/Vaginal Functioning

28.8 ± 21

31.9 ± 25.9

0.748

36.5 ± 15.4

30.2 ± 23.1

20.2 ± 22.5

0

0.288

Lymphoedema

8.1 ± 16.8

7 ± 19.9

0.188

5.7 ± 15.6

7.6 ± 18.0

10.6 ± 17.8

16.7 ± 33.8

0.239

Peripheral Neuropathy

21.3 ± 26

26.7 ± 35.4

0.670

27.6 ± 33.4

22.8 ± 30.0

26.1 ± 29.9

23.3 ± 22.2

0.618

Menopausal Symptoms

14.5 ± 28.5

24.8 ± 34

0.004

5.7 ± 15.6

15.5 ± 29.2

26.2 ± 30.4

23.3 ± 37.7

0.018

Sexual Worry

46.2 ± 43.7

43.8 ± 43.8

0.591

44.1 ± 45

47 ± 43.6

46.8 ± 43.5

50.0 ± 47.5

0.986

QLQ-CX24 Functional scales

Sexual Activity

9.5 ± 19

8.1 ± 19.1

0.352

11.8 ± 22

10.8 ± 20.1

6.4 ± 19.7

0

0.137

Sexual Enjoyment

44 ± 28.3

43.1 ± 36.8

0.977

37.5 ± 37.5

43.8 ± 30.2

47.6 ± 29.8

0

0.763

  1. Values are in mean score ± SD. Significance P < 0.05 by Kruskal Wallis test* or Mann Whitney U test# as appropriate and significant values are bolded
Back to article page

BMC Women's Health

ISSN: 1472-6874

Contact us